0001615774-18-005290.txt : 20180614
0001615774-18-005290.hdr.sgml : 20180614
20180614160620
ACCESSION NUMBER: 0001615774-18-005290
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180612
FILED AS OF DATE: 20180614
DATE AS OF CHANGE: 20180614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEDERMAN SETH
CENTRAL INDEX KEY: 0001563420
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36019
FILM NUMBER: 18899211
MAIL ADDRESS:
STREET 1: C/O TONIX PHARMACEUTICALS HOLDING CORP
STREET 2: 509 MADISON AVE., SUITE 306
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp.
CENTRAL INDEX KEY: 0001430306
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261434750
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 509 MADISON AVE. - SUITE 306
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 1-800-849-7894
MAIL ADDRESS:
STREET 1: 509 MADISON AVE. - SUITE 306
CITY: NEW YORK
STATE: NY
ZIP: 10022
FORMER COMPANY:
FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC.
DATE OF NAME CHANGE: 20080320
4
1
s110815_form4.xml
4
X0306
4
2018-06-12
0
0001430306
Tonix Pharmaceuticals Holding Corp.
TNXP
0001563420
LEDERMAN SETH
C/O TONIX PHARMACEUTICALS HOLDING CORP.
509 MADISON AVENUE, SUITE 306
NEW YORK
NY
10022
1
1
0
0
Chief Executive Officer
Common Stock, $0.001 par value
2018-06-12
4
P
0
1000
4.37
A
16166
D
Common Stock, $0.001 par value
2018-06-12
4
P
0
2000
4.37
A
20463
I
By Lederman & Co., LLC
Common Stock, $0.001 par value
22700
I
By 401(k) plan
Common Stock, $0.001 par value
45900
I
By IRA account
Common Stock, $0.001 par value
3100
I
By spouse
Common Stock, $0.001 par value
2.917
I
By Leder Laboratories, Inc.
Common Stock, $0.001 par value
2917
I
By Starling Pharmaceuticals, Inc.
Common Stock, $0.001 par value
3246
I
By L&L Technologies, LLC
Common Stock, $0.001 par value
5898
I
By Targent Pharmaceuticals, LLC
Reporting person may be deemed to be a control person of this entity.
/s/ Seth Lederman
2018-06-14